# Jeni Lee

> Jeni Lee is a Series A investor at Pivotal bioVenture Partners backing Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pivotal bioVenture Partners](https://shizune.co/investors/profile/pivotal-bioventure-partners)
- Location: San Francisco Bay Area, United States
- Total investments: 3
- Last investment: Dec 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jeniklee/

Jeni Lee is a Series A investor at Pivotal bioVenture Partners in San Francisco Bay Area focused on Biotechnology and Health Care. Jeni Lee is the Board Member of Mosanna Therapeutics. She attended the University of California.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Health Care | 2 | 67% |
| Therapeutics | 2 | 67% |
| Medical | 1 | 33% |
| Life Science | 1 | 33% |

6 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Switzerland | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Addition Therapeutics | Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies. | $100M | Series A | Dec 17, 2025 |  |
| Mosanna Therapeutics | Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. | $80M | Series A | Jun 09, 2025 |  |
| DermBiont | DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes(fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California. | $28M | Series A | Dec 21, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Norwest](https://shizune.co/investors/profile/norwest-venture-partners) — VC Fund, 2 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [BEVC](https://shizune.co/investors/profile/bevc) — VC Fund, 1 deal together
- [Bill & Melinda Gates Foundation](https://shizune.co/investors/profile/bill-melinda-gates-foundation) — VC Fund, 1 deal together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 1 deal together

## About Pivotal bioVenture Partners

VC Fund · San Francisco, United States

Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. They invest at all stages in a company’s evolution, from company creation through midand late stage clinical development. Their team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses.

5 contacts available at Pivotal bioVenture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Ash Khanna | Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune | https://shizune.co/investors/profile/ash-khanna |
| Heather Preston | Managing Partner | https://shizune.co/investors/profile/heather-preston |
| Jeni Lee | Partner | https://shizune.co/investors/profile/jeni-lee-ba22 |
| Robert Hopfner | Managing Partner | https://shizune.co/investors/profile/rob-hopfner |
| Vincent Cheung | Managing Partner | https://shizune.co/investors/profile/vincent-cheung-2 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jeni Lee invest in?

Jeni Lee invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jeni Lee last invest?

The most recent investment recorded for Jeni Lee closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co